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Cre-mediated site-specific recombination has emerged as an indispensable tool for the precise 
manipulation of genomes allowing lineage tracing studies, temporal and spatial misexpressions 
and in particular the generation of conditional knockout alleles. Previously, we and others showed 
that Cre and its ligand inducible variant CreERT2 are also highly efficient in the developing and 
adult zebrafish. The number of Cre driver and effector lines is currently still limited in zebrafish. 
However, the recent advent of novel genome editing tools such as TALEN and CRISPR/Cas will 
significantly increase interest in the conditional Cre/lox-technology in this organism. The 
considerations of basic transgene design and subsequent transgenesis have been addressed 
elsewhere. Here we outline practical experimental steps for transient functionality tests of CreERT2 
driver and effector constructs. In addition, we introduce detailed protocols to elicit CreERT2-
mediated recombination in vivo at embryonic as well as adult stages.  
1. Introduction 
 
Site-specific recombinases promote strand exchanges between two sequence-specific target sites 
without any additional cofactors [1]. The most commonly used recombinase is the bacteriophage 
P1-derived cyclic recombinase Cre, which catalyzes site-specific recombination between two loxP 
target sites. Each loxP site consists of two 13-bp repeats flanking an 8-bp asymmetric spacer 
sequence that confers directionality (Fig. 1A). Head-to-head orientation causes inversion of the 
DNA between the two target sites, whereas head-to-tail orientation results in the excision of the 
intervening DNA sequence, an irreversible reaction due to the rapid loss of the excised product 
(Fig. 1A). Temporal control of recombination can be achieved by using recombinases fused to a 
ligand-binding domain of a steroid hormone receptor [2]. Only administration of the ligand results 
in the translocation of the recombinase to the nucleus, where it catalyzes the recombination event 
(Fig. 1B). Currently, Cre fused to the mutated human ligand-binding domain of the estrogen 
receptor (CreERT2) has the best properties for ligand sensitivity and inducible recombination 
efficiency [3]. 
Previous attempts to establish the Cre/lox system in zebrafish showed its general functionality 
[4,5] but recombination frequencies were very low [6,7]. The reason of this inefficiency is still 
unknown but the transgenesis approach might be crucial. Initially, transgenic zebrafish were 
generated by microinjection of naked plasmid DNA into the cytoplasm of one cell-stage embryos 
resulting in tandem arrays  or concatemeric DNA integration of up to 2000 copies [8]. In contrast, 
single integration events using transposon-mediated transgenesis resolved these issues [9,10] 
and has triggered a strong increase in Cre/lox applications in zebrafish [11-15]. The methodology 
of transposon-mediated transgenesis in general and considerations of basic transgene design for 
Cre/lox recombination experiments in particular have been addressed previously [16,17]. Here in 
this chapter we aim to provide detailed practical experimental steps for transient functionality tests 
of CreERT2 driver and effector constructs and step by step protocols for ligand-mediated CreERT2 
activation in vivo at embryonic as well as adult stages.  
2. Material 
1. Fish tanks and systems for maintenance and breeding of fish (Aqua Schwarz GmbH). 
2. Fish food: paramecia. 
3. Fish food: brine shrimp. 
4. Fish food: Tetramin flakes. 
 
2.1 Transient functionality tests of CreERT2 driver and effector constructs by microinjection 
1. Needle puller (Flaming/Brown P-97 Micropipette Puller, Sutter Instrument Co.). 
2. Glass capillaries (WPI, TW100-3 for injection). 
3. Microinjector (WPI, PV820 pneumatic Pico Pump with foot pedal). 
4. Micromanipulator (Narishige M-152). 
5. Ball-joint-holder (WPI). 
6. Magnet holder MB-B (Kanetec). 
7. Petri dish, diameter: 60 mm. 
8. Watchmaker forceps. 
9. Dissecting scope (Olympus SZX16). 
10. E3 embryo medium: 5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4, 0.0002 % 
methylene blue (pH adjusted to 7.2 with NaOH). 
11. 2 % phenol red (RNase-free). 
12. Microloader tips (Eppendorf). 
13. Fluorescent stereoscope (Olympus MVX10). 
 
2.1.1 Transient functionality test of CreERT2 driver constructs 
Injection of a novel CreERT2 driver construct into the established Cre effector line 
Tg(hsp70l:LOXP-DsRed2-LOXP-EGFP)tud107 
1. Novel CreERT2 driver construct (endotoxin-free). 
2. Wild-type fish (AB). 
3. Tg(hsp70l:LOXP-DsRed2-LOXP-EGFP)tud107 (a Cre-dependent reporter line which expresses 
DsRed2 in the absence of Cre activity but changes to EGFP after a successful recombination 
event [12]). 
4. 50 mM Tamoxifen (TAM; Sigma) in DMSO or 25 mM 4-Hydroxytamoxifen (4-OHT; Sigma) in 
EtOH. (Prolonged storage decreases potency of 4-OHT. Use of fresh or recently dissolved 4-OHT 
is advised [16].) 
5. Water bath (GFL 1002). 
 
Injection of a novel CreERT2 driver construct along with pTol(hsp70l:LOXP-DsRed2-LOXP-EGFP) 
into wild-type embryos 
1. pTol(hsp70l:LOXP-DsRed2-LOXP-EGFP) (an established effector construct) (endotoxin-free).  
 
2.1.2 Transient functionality test of CreERT2 effector constructs 
Injection of a novel Cre effector construct into the established CreERT2 driver line 
Tg(her4.1:mCherry-CreERT2)tud106 
1. Novel CreERT2 effector construct (endotoxin-free). 
2. Tg(her4.1:mCherry-CreERT2)tud106 (an established CreERT2 driver line which expresses 
CreERT2 under the control of a her4.1 promoter fragment) [12]. 
 
Injection of a novel Cre effector construct along with Cre mRNA into wild-type embryos 
1. pCS2+ Cre (a plasmid to synthesize Cre mRNA) [5]. 
2. NotI. 
3. Gel and PCR clean up kit (NucleoSpin Extract II kit, Machery-Nagel). 
4. mMESSAGE mMACHINE SP6 kit (Ambion). 
 
2.2 CreERT2 mediated site-specific recombination at embryonic stages 
1. Dimethyl sulfoxide (DMSO).  
2. Embryo lysis buffer: 10 mM Tris-HCl (pH 8.2), 10 mM EDTA, 200 mM NaCl, 0,5 % SDS, 200 
µg/mL Proteinase K. 
3. 100% and 70% ice cold EtOH. 
4. Table-top centrifuge (Pico 21, Thermo). 
5. PCR machine (Eppendorf Mastercycler ep Gradient S). 
6. Primer for amplification: hsp70l-for 5'-CCCCGACGAGGTGTTTATTCGCTC- 3'; GFP-rev 5’-
CCGTCCAGCTCGACCAGGATG-3’. 
7. PCR tubes. 
8. PCR reagents: 10 mM dNTP mix, DreamTaq (Fermentas). 
9. Electrophoreses chamber and power supply. 
10. DNA Ladder (GeneRuler 1 kb Plus DNA Ladder, Fermentas). 
 
2.3 CreERT2 mediated site-specific recombination in the adult central nervous system 
1. Heat shock unit (Immersion Thermostat LAUDA Ecoline Staredition E 200).  
2. Tricaine methane sulfonate solution: 200-300 mg/l. 
3. 0,5 M phosphate buffer: 94 mM NaH2PO4, 0.4 M Na2HPO4, pH 7.5. 
4. 4 % paraformaldehyde / 0.1 M phosphate buffer, pH 7.5. 
5. 20 % sucrose / 0.5 M EDTA in 0.1 M phosphate buffer, pH 7.5. 
6. 7.5 % gelatin / 20 % sucrose in 0.1 M phosphate buffer, pH 7.5.  
7. Cryostat (Kryostat HM 560”, Microm). 
8. PBSTX: 1x PBS, 0.3% TritonX (w/v). 
9. Humid chamber: rectangular petri dish with wet paper towel. 
10. Anti-GFP antibody (ABcam, Ab13970). 
11. Alexa Fluor® 488 Goat Anti–Chicken (Molecular Probes). 
12. 1 µg/ml DAPI in PBSTX. 
13. 70 % glycerol/PBS. 
14. Fluorescent microscope (Zeiss Axio Imager Z1).  
3. Methods 
The Cre/lox system is a genetic two component transgene system with Cre driver lines expressing 
Cre under the control of a specific promoter and Cre effector lines driving a loxP-flanked cassette 
upstream of a second cassette containing the gene of interest (Fig. 2). Successful recombination 
events can be proven using polymerase chain reaction (PCR), immunohistochemistry or native 
fluorescence depending on the nature of the Cre effector line (see note 1). Subsequently, we 
describe the execution of the before-mentioned methods in detail for transient functionality tests 
of CreERT2 driver and effector constructs and CreERT2 mediated site-specific recombination at 
embryonic as well as adult stages. However, the described methods are not restricted for the 
individual purpose and can be applied for the others as well.   
 
3.1 Transient functionality tests of CreERT2 driver and effector constructs by microinjection 
It is pivotal to verify the functionality of newly cloned CreERT2 driver or effector constructs prior to 
the establishment of the respective transgenic line. This can be easily achieved by microinjection 
of the newly generated CreERT2 driver or effector construct into an existing effector or CreERT2 
driver line, respectively. Alternatively, simultaneous microinjection of the newly generated CreERT2 
driver construct along with an established effector construct or the newly generated effector 
construct along with Cre mRNA can be employed.  
 
3.1.1 Transient functionality test of CreERT2 driver constructs 
Injection of a novel CreERT2 driver construct into the established Cre effector line 
Tg(hsp70l:LOXP-DsRed2-LOXP-EGFP)tud107 
1. Pull needles using needle puller and glass capillaries to obtain rigid, non-flexible needles 
which are sealed at the tip. (Our parameters: Heat: 535; Pressure: 250; Velocity: 250; Time: 150). 
2. Place female and male zebrafish of wild-type and Tg(hsp70l:LOXP-DsRed2-LOXP-EGFP)tud107 
background in mating boxes separated by a divider in the evening prior to the injection day. Next 
morning combine fish to elicit mating. Microinjection should be carried out at the 1-cell stage (0-
30 min post fertilization). Several fish couples can be used subsequently to ensure a constant 
supply of freshly laid eggs.  
3. Prepare injection solution: 35 µg/µl novel CreERT2 driver construct, 0,2 % phenol red. 
4. Load needle with 2 µl injection solution using a microloader tip. 
5. Place 20-25 embryos in a petri dish with E3 medium into the field of view of the dissecting 
scope. Attach needle to the holder of the micromanipulator and adjust it to a 45° angle. Lower the 
needle tip into the focus plane of the embryos. 
6. Open the needle with a pair of sharp watchmaker forceps and adjust the hold pressure. Inject 
1-4 nl of the injection solution into the cytoplasm. A drop of mineral oil on a micrometer can be 
used to calculate the volume of each injection. When injected into the oil, a bead with a diameter 
of 0.1 mm contains 500 pL of injection material [18].Carry out injections using the up and down 
control of the micromanipulator only. Injected embryos can stick to the needle but are released if 
the needle is pulled out of the E3 medium. 
7. Transfer injected embryos into a fresh petri dish containing E3 medium. Continue injections, 
collect injected embryos in the same petri dish and transfer them into a 28°C incubator when 
finished. 
8. Thaw 50 mM TAM or 25 mM 4-OHT stock 8 hours post injection and prepare E3 medium 
containing 5 µM TAM or 5 µM 4-OHT, respectively (see note 2). 
9. Remove dead and malformed embryos from the injected clutch. Replace E3 medium with 
working E3/TAM or E3/4-OHT solution and incubate at 28°C overnight.  
10. Preheat E3 medium in a 42°C water bath in the evening prior to the heat shock. 
11. Next morning, remove working E3/TAM or E3/4-OHT solution entirely, pour in preheated E3 
medium and incubate in a 37°C incubator for 60 min (see note 3). 
12. Transfer petri dish back to 28°C and observe GFP expression under a fluorescent stereoscope 
3 hours post heat shock. Presence of GFP indicates functionality of the novel CreERT2 driver 
construct. If no GFP signal was observed, check for DsRed fluorescence 24h post heat shock to 
validate the efficiency of the heat shock (see note 4). 
 
Injection of a novel CreERT2 driver construct along with pTol(hsp70l:LOXP-DsRed2-LOXP-EGFP) 
into wild-type embryos 
1. Place wild-type female and male zebrafish in mating boxes separated by a divider in the evening 
prior to the injection day. 
2. Prepare injection solution: 20 µg/µl novel CreERT2 driver construct, 20 µg/µl pTol(hsp70l:LOXP-
DsRed2-LOXP-EGFP), 0,2 % phenol red. 
3. Perform microinjection, pharmacological treatment, heat shock and fluorescent analysis as 
described above. GFP expression might be present even without a heat shock because the hsp70l 
promoter is transiently active when not integrated into the genome. However, expression levels 
are significantly increased after heat shock. 
 
3.1.2 Transient functionality test of fluorescent CreERT2 effector constructs 
Injection of a novel fluorescent CreERT2 effector construct into an existing driver line 
1. Place female (wild-type) and male (Tg(her4.1:mCherry-CreERT2)tud106) zebrafish in mating 
boxes separated by a divider in the evening prior to the injection day.  
2. Prepare injection solution: 35 µg/µl novel CreERT2 effector construct, 0,2 % phenol red. 
3. Perform microinjection, pharmacological treatment, heat shock and fluorescent analysis as 
described above.  
 
Injection of a novel fluorescent CreERT2 effector construct along with Cre mRNA into wild-type 
embryos 
1. Linearize pCS2+ Cre using NotI. Purify with Gel and PCR clean up kit and elute with nuclease-
free water. 
2. Use 1 µg of linearized plasmid for in vitro transcription with mMESSAGE mMACHINE SP6 kit 
according to the manufacturer’s instructions. 
3. Place wild-type female and male zebrafish in mating boxes separated by a divider in the evening 
prior to the injection day.  
4. Prepare injection solution: 35 µg/µl novel CreERT2 effector construct, 25 ng/μl Cre mRNA, 0,2 
% phenol red. 
5. Perform microinjection, pharmacological treatment, heat shock and fluorescent analysis as 
described above. 
 
3.2 CreERT2 mediated site-specific recombination at embryonic stages 
1. Breed Tg(hsp70l:LOXP-DsRed2-LOXP-EGFP)tud107 females with Tg(her4.1:mCherry-
CreERT2)tud106 males. It is highly recommended to use male CreERT2 driver lines in order to avoid 
unwanted maternal recombinase contribution [16].   
2. Collect progeny, remove unfertilized embryos and transfer into a 28°C incubator. 
3. Perform pharmacological treatment as described above. Retain DMSO control sample. 
4. At 24 hours post fertilization transfer embryos into 1,5 ml tube. Remove E3 medium, add 500 
µl embryo lysis buffer and incubate at 55°C in shaker until clear. 
5. Add 1000 µl ice-cold 100% EtOH and centrifuge for 10 min at full speed. 
6. Discard supernatant, add 200 µl ice-cold 70% EtOH and centrifuge for 2 min at full speed. 
7. Discard supernatant, dry pellet and add H2O with 4µl per embryo. 
8. Mix 4 µl of the sample with 2 µl 10x reaction buffer, 0,8 µl dNTP mix (10mM each), 0,5 µl hsp70l-
forward primer (20µM), 0,5 µl GFP-reverse primer, 0,2 µl DreamTaq polymerase and 12 µl H2O. 
PCR reaction was run in a thermocycler with the following program: 94°C for 30 sec; 32 cycles of 
94°C for 30 sec, 62°C for 30 sec, 72°C for 120 sec; followed by 72°C for 8 min. 
9. Check PCR samples by agarose gel electrophoresis (1,2 %). Presence of a 525 base pair 
fragment reveals successful recombination whereas the 1744 base pair amplicon is the un-
recombined control. 
 
3.3 CreERT2 mediated site-specific recombination in the adult central nervous system 
1. Breed Tg(hsp70l:LOXP-DsRed2-LOXP-EGFP)tud107 females with Tg(her4.1:mCherry-
CreERT2)tud106 males. Collect progeny, remove unfertilized embryos and transfer into a 28°C 
incubator. 
2. At 24 hours post fertilization, sort mCherry-positive embryos under a fluorescent stereoscope. 
Discard mCherry-negative siblings. Perform heat shock as described above. Check for GFP 
expression under a fluorescent stereoscope 3 hours post heat shock. Presence of GFP indicates 
unconditional recombination (leakiness) of the CreERT2 driver. 
3. Check for DsRed fluorescence 24h post heat shock. Select DsRed-positive embryos which 
represent double transgenic animals carrying CreERT2 driver and effector constructs. Incubate 
double transgenic fish at 28°C (see note 5). 
4. At 5 days post fertilization transfer animals to a nursery of a fish facility providing paramecia, 
brine shrimp and Tetramin flakes according to established guidelines [19]. 
5. At 6 months post fertilization, place 4 adult zebrafish in a 1000 ml beaker with 750 ml system 
water and 2.5 μM TAM. Cover with aluminum foil, provide air supply and incubate overnight. 
Perform three consecutive overnight treatments with a 12 hour resting period in between. Wash 
fish several times in system water prior to transfer back to fish facility. 
6. After a one month chase period, transfer TAM-treated fish to the heat shock unit and apply a 2 
hour heat shock on two consecutive days. Using the Immersion Thermostat LAUDA Ecoline 
Staredition E 200 we employ the heat shock profile presented in Table 1. Briefly, water 
temperature is slowly increased from 28°C to 37.5°C over the course of 30 min, maintained at 
37.5°C for 90 min and steadily decreased to 28°C over 60 min. 
7. Euthanize fish 5 hours post second heat shock by overdosing with tricaine methane sulfonate. 
Carefully open the skull with watchmaker forceps and fix brains within the skull at 4°C overnight 
in 4 % paraformaldehyde / 0.1 M phosphate buffer, pH 7.5. 
8. Wash twice for 15 min with 0.1 M phosphate buffer, pH 7.5 and transfer for decalcification and 
cryoprotection to 20 % sucrose / 0,5 M EDTA in 0.1 M phosphate buffer, pH 7.5. Incubate at 4°C 
for 24 hours. 
9. Place the heads/brains in 7.5 % gelatin / 20 % sucrose in 0.1 M phosphate buffer, pH 7.5 at 
37°C for 10min. Freeze brains in 7.5 % gelatin / 20 % sucrose in 0.1 M phosphate buffer, pH 7.5 
and prepare 10-16µm cryosections using a cryostat. 
10. Dry sections for 30 min at room temperature and store at -20°C. 
11. Thaw sections for 10-30 min at room temperature. Incubate for an hour in 100 % ice-cold 
Methanol at -20°C and rehydrate for 15 min in PBSTX on a shaker. 
12. Incubate sections with anti-GFP antibody diluted 1:2500 in PBSTX in a humid chamber at 4°C 
overnight. 
13. Wash sections 3 times for 10 min in PBSTX on a shaker and incubate with Alexa Fluor® 488 
Goat Anti–Chicken diluted 1:500 in PBSTX in a humid chamber for 1-2 hours. 
14. Incubate sections in DAPI solution for 3 min. 
15. Wash sections 3 times for 10 min in PBSTX on a shaker and mount in 70 % glycerol/PBS. 
16. Analyze GFP expression using a fluorescent microscope. 
 
 Table1: Heat shock profile 
segment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
°C 28 29 30 31 32 33 34 35 36 37 37.5 34 31 28 




1. Validation of successful recombination is easily determined by native fluorescence. It is 
therefore advisable to include a fluorescent protein in the second cassette containing the gene of 
interest. This can be either a direct fusion or via the viral T2A peptide sequence allowing equimolar 
production of two proteins from a single open reading frame [20]. 
2. Time point of TAM/4-OHT application depends on CreERT2 expression and the corresponding 
experiment. 
3. When using hsp70l promoter driven effector lines, a heat shock can be applied immediately 
after TAM removal at embryonic stages. In contrast, larval and adult animals are more susceptible 
and require time – in our experience at least 24h - to recover prior to heat shock. Treatment with 
4-OHT (up to 10µM) followed by an immediate heat shock however does not result in fatal 
consequences. 
4. Use of hsp70l promoter driven effector lines requires heat shocking to activate the effector 
construct. In contrast, ubiquitin B (ubb) driven effector lines like ubi:Switch [14] and ubi:Zebrabow 
[15] are constitutively active at all stages of zebrafish development and in adulthood. In our lab, 
we have used both approaches and based on our experience the optimal Cre effector line requires 
individual elucidation. 
5. Alternatively, double transgenic animals can be identified using allele-specific PCRs on genomic 
DNA extracted from fin clips of adult fish. 
 
5. Figure legends 
Figure 1: (A) Basic principles of Cre/lox. The Cre/lox system comprises the site-specific 
recombinase Cre and its target site loxP which consist of an 8 bp spacer, flanked by two 13 bp 
inverted repeats. Orientation of two loxP target sites determines the outcome of the recombination 
event. Head-to-head orientation causes inversion of the DNA between the two sites, whereas 
head-to-tail orientation results in the excision of the intervening DNA sequence. (B) Scheme of 
the ligand-dependent recombination in cells of a red-to green reporter. Due to binding to heat 
shock protein 90 (Hsp90), the chimeric CreERT2 recombinase is retained in the cytoplasm in the 
absence of the ligand. Upon administration of Tamoxifen which is converted to the active ligand 
4-Hdroxytamoxifen (4-OHT), CreERT2 translocates to the nucleus catalyzing the recombination 
event. 
 
Figure 2: The Cre/lox system is a binary system consisting of a Cre driver and an effector line. 
Most commonly, Cre is driven by a cell-or tissue specific promoter (promoter A) providing spatial 
control whereas the effector is regulated by a ubiquitous promoter (promoter B) driving expression 
of a loxP-flanked marker or STOP cassette. This cassette is followed by a second cassette or 
gene of interest (GOI). In cells of double transgenic animals carrying Cre driver and effector 
transgenes, Cre elicits recombination once promoter A is activated, putting the second cassette 
or GOI under the control of promoter B. 
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